One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Tuesday, as the share price of this fund traded down over 2% in the day’s session. The fund’s share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 228,234 shares of Takeda Pharma. At Tuesday’s closing price, this would have valued this sale at roughly $3.9 million. This is only a small fraction of the total holdings. This fund is up 88% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
|ARKF||TCSLI||TCS GROUP HOLDING PLC||50,650|
|ARKG||PSTI||PLURISTEM THERAPEUTICS INC||1,131|
|ARKG||SRPT||SAREPTA THERAPEUTICS INC||48,004|
|ARKG||TAK||TAKEDA PHARMACEUTICAL CO LTD||228,234|
|ARKK||ICE||INTERCONTINENTAL EXCHANGE INC||196,304|
|ARKQ||RAVN||RAVEN INDUSTRIES INC||32,733|
|ARKQ||GLEO||GALILEO ACQUISITION CORP||5,888|
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.